Literature DB >> 26171146

Dual isotope simultaneous imaging to evaluate the effects of intracoronary bone marrow-derived mesenchymal stem cells on perfusion and metabolism in canines with acute myocardial infarction.

Linjun Hao1, Jin Hao2, Wei Fang3, Chunlei Han4, Kaixiu Zhang5, Xuemei Wang5.   

Abstract

Stem cell therapy on acute myocardial infarction (AMI) has been performed for over a decade. In the present study, cardiac perfusion, metabolism and function in dogs with AMI treated by intracoronary injection of bone marrow-derived mesenchymal stem cells (MSCs) were evaluated by dual isotope simultaneous acquisition (DISA) of single positron emission computed tomography (SPECT). Dogs (n=12, 20-30 kg) were randomly assigned to two groups: A graft study (n=6) and control group (n=6). Bone marrow mesenchymal aspirate was collected 3 weeks before surgical procedure. Stem cells were induced by 5-azacytidine for differentiation into myocytes. The dog AMI model was produced by blocking the blood stream at 1/3 of the distinct left anterior descending coronary artery for 90 min. For dogs in the grafting group, MSCs were transplanted by intracoronary injection, and for the control group, 0.9% NaCl was injected instead. At 1 and 10 weeks after MSCs were grafted, respectively, SPECT DISA was performed for each dog in the two groups with 99mTc-SPECT MIBI (925 MBq) and 18F-FDG (222 MBq) for evaluation of myocardial perfusion and metabolism. After the dogs were sacrificed, heart tissue was stained by myocyte-specific antibodies for newborn vessels, troponin T and bromodeoxyuridine (BrdU). Following induction by 5-azacytidine, the morphological features with colony formation, microfilament, as well as atrial granules and positive stainings of α-actinin, myosin and troponin I demonstrated strongly that the MSCs differentiated into myocytes. The number of viable myocardial segments was 10 in the grafting group, which was significantly greater compared with the control group. The ejection fraction of the infarcted left ventricle (LVEF,%) increased from 53.80±9.58 to 70.00±7.52 (change, 16.20±2.93) at 1 and 10 weeks after MSCs engraftment, whilst in the control group, LVEF was 50.50±8.02 and 56.50±7.24 (change, 5.50±2.69), respectively. The LVEF difference was statistically significant (P<0.05) between the graft and control groups. Furthermore, immunostaining of all the myocyte-specific antibodies (for newly born vessels, troponin T and BrdU) was positive. In conclusion, direct intracoronary injection of bone marrow MSCs into injured myocardium in the experimental dog AMI model can significantly improve cardiac function with new vessel formation and myocyte-specific biomarker expression, and in particular, the present study further shows that DISA SPECT can be used for the assessment of stem cell transplantation in the heart.

Entities:  

Keywords:  acute myocardial infarction; metabolism; perfusion; stem cell

Year:  2015        PMID: 26171146      PMCID: PMC4486876          DOI: 10.3892/br.2015.474

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  18 in total

Review 1.  PET: Is myocardial flow quantification a clinical reality?

Authors:  Antti Saraste; Sami Kajander; Chunlei Han; Sergey V Nesterov; Juhani Knuuti
Journal:  J Nucl Cardiol       Date:  2012-10       Impact factor: 5.952

2.  The role of PET with 13N-ammonia and 18F-FDG in the assessment of myocardial perfusion and metabolism in patients with recent AMI and intracoronary stem cell injection.

Authors:  Massimo Castellani; Alessandro Colombo; Rosaria Giordano; Enrico Pusineri; Cristina Canzi; Virgilio Longari; Emanuela Piccaluga; Simone Palatresi; Luca Dellavedova; Davide Soligo; Paolo Rebulla; Paolo Gerundini
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

Review 3.  Primary PCI for myocardial infarction with ST-segment elevation.

Authors:  Ellen C Keeley; L David Hillis
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

Review 4.  Imaging techniques in nuclear cardiology for the assessment of myocardial viability.

Authors:  Riemer H J A Slart; Jeroen J Bax; Dirk J van Veldhuisen; Ernst E van der Wall; Rudi A J O Dierckx; Pieter L Jager
Journal:  Int J Cardiovasc Imaging       Date:  2005-12-13       Impact factor: 2.357

Review 5.  The origins of SPECT and SPECT/CT.

Authors:  Brian F Hutton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-12       Impact factor: 9.236

Review 6.  Systems approaches to preventing transplanted cell death in cardiac repair.

Authors:  Thomas E Robey; Mark K Saiget; Hans Reinecke; Charles E Murry
Journal:  J Mol Cell Cardiol       Date:  2008-03-19       Impact factor: 5.000

Review 7.  Mesenchymal stem cells and their potential as cardiac therapeutics.

Authors:  Mark F Pittenger; Bradley J Martin
Journal:  Circ Res       Date:  2004-07-09       Impact factor: 17.367

Review 8.  Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review.

Authors:  Enca Martin-Rendon; Susan J Brunskill; Chris J Hyde; Simon J Stanworth; Anthony Mathur; Suzanne M Watt
Journal:  Eur Heart J       Date:  2008-06-03       Impact factor: 29.983

9.  Circulating bone marrow stem/progenitor cells in vascular atherogenesis and in the noninvasive diagnosis of coronary stenosis.

Authors:  Emma L Soboleva; Zufar A Gabbasov; Alexander A Agapov; Renat S Akchurin; Olga S Saburova; Yury A Romanov; Vladimir N Smirnov
Journal:  Exp Clin Cardiol       Date:  2005

10.  Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction: head-to-head comparison between 99mTc-sestamibi/18F-FDG DISA SPECT and 13N-ammonia/ 18F-FDG PET.

Authors:  Riemer H J A Slart; Jeroen J Bax; Dirk J van Veldhuisen; Ernst E van der Wall; Roy Irwan; Wim J Sluiter; Rudi A Dierckx; Jaep de Boer; Pieter L Jager
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-08       Impact factor: 9.236

View more
  6 in total

1.  Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.

Authors:  Eric G Schmuck; Timothy A Hacker; David A Schreier; Naomi C Chesler; Zhijie Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-01       Impact factor: 4.733

2.  Protective effect of MitoQ on oxidative stress-mediated senescence of canine bone marrow mesenchymal stem cells via activation of the Nrf2/ARE pathway.

Authors:  Lijun Zhong; Jiaqiang Deng; Congwei Gu; Liuhong Shen; Zhihua Ren; Xiaoping Ma; Qigui Yan; Junliang Deng; Zhicai Zuo; Ya Wang; Suizhong Cao; Shumin Yu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-09-13       Impact factor: 2.416

3.  Correlation between thoracic aorta 18F-natrium fluoride uptake and cardiovascular risk.

Authors:  Francesco Fiz; Silvia Morbelli; Matteo Bauckneht; Arnoldo Piccardo; Giulia Ferrarazzo; Alberto Nieri; Nathan Artom; Manlio Cabria; Cecilia Marini; Marco Canepa; Gianmario Sambuceti
Journal:  World J Radiol       Date:  2016-01-28

Review 4.  Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).

Authors:  Aastha Singh; Abhishek Singh; Dwaipayan Sen
Journal:  Stem Cell Res Ther       Date:  2016-06-04       Impact factor: 6.832

5.  Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction.

Authors:  Meikuang Lim; Weiqiang Wang; Lu Liang; Zhi-Bo Han; Zongjin Li; Jie Geng; Meng Zhao; Honghong Jia; Jie Feng; Zhe Wei; Baoquan Song; Jiemin Zhang; Jun Li; Tianwen Liu; Fan Wang; Ting Li; Jianming Li; Yihu Fang; Jianhua Gao; Zhongchao Han
Journal:  Stem Cell Res Ther       Date:  2018-05-11       Impact factor: 6.832

Review 6.  Efficacy of Stem Cell Therapy in Large Animal Models of Ischemic Cardiomyopathies: A Systematic Review and Meta-Analysis.

Authors:  Debora La Mantia; Chiara Bernardini; Augusta Zannoni; Roberta Salaroli; Changzhen Wang; Silvia Bencivenni; Monica Forni
Journal:  Animals (Basel)       Date:  2022-03-16       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.